Department of Radiology, Nuclear Medicine & Anatomy, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands.
Department of Surgical Oncology, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands.
Clin Cancer Res. 2020 Nov 15;26(22):5934-5942. doi: 10.1158/1078-0432.CCR-20-2255. Epub 2020 Sep 8.
Intraoperative image guidance may aid in clinical decision-making during surgical treatment of colorectal cancer. We developed the dual-labeled carcinoembryonic antigen-targeting tracer, [In]In-DTPA-SGM-101, for pre- and intraoperative imaging of colorectal cancer. Subsequently, we investigated the tracer in preclinical biodistribution and multimodal image-guided surgery studies, and assessed the clinical feasibility on patient-derived colorectal cancer samples, paving the way for rapid clinical translation.
SGM-101 was conjugated with p-isothiocyanatobenzyl-diethylenetriaminepentaacetic acid (DTPA) and labeled with Indium-111 (In). The biodistribution of 3, 10, 30, and 100 μg [In]In-DTPA-SGM-101 was assessed in a dose escalation study in BALB/c nude mice with subcutaneous LS174T human colonic tumors, followed by a study to determine the optimal timepoint for imaging. Mice with intraperitoneal LS174T tumors underwent micro-SPECT/CT imaging and fluorescence image-guided resection. In a final translational experiment, we incubated freshly resected human tumor specimens with the tracer and assessed the tumor-to-adjacent tissue ratio of both signals.
The optimal protein dose of [In]In-DTPA-SGM-101 was 30 μg (tumor-to-blood ratio, 5.8 ± 1.1) and the optimal timepoint for imaging was 72 hours after injection (tumor-to-blood ratio, 5.1 ± 1.0). In mice with intraperitoneal tumors, [In]In-DTPA-SGM-101 enabled preoperative SPECT/CT imaging and fluorescence image-guided resection. After incubation of human tumor samples, overall fluorescence and radiosignal intensities were higher in tumor areas compared with adjacent nontumor tissue ( < 0.001).
[In]In-DTPA-SGM-101 showed specific accumulation in colorectal tumors, and enabled micro-SPECT/CT imaging and fluorescence image-guided tumor resection. Thus, [In]In-DTPA-SGM-101 could be a valuable tool for preoperative SPECT/CT imaging and intraoperative radio-guided localization and fluorescence image-guided resection of colorectal cancer.
术中图像引导可能有助于指导结直肠癌手术治疗中的临床决策。我们开发了双标记癌胚抗原靶向示踪剂 [In]In-DTPA-SGM-101,用于结直肠癌的术前和术中成像。随后,我们在临床前生物分布和多模态图像引导手术研究中研究了示踪剂,并在患者来源的结直肠癌样本上评估了其临床可行性,为快速临床转化铺平了道路。
SGM-101 与对异硫氰酸苯甲基-二乙三胺五乙酸(DTPA)偶联,并与铟-111(In)标记。在 BALB/c 裸鼠皮下 LS174T 人结肠肿瘤中进行剂量递增研究,评估 3、10、30 和 100μg [In]In-DTPA-SGM-101 的生物分布,然后进行研究以确定成像的最佳时间点。患有腹腔 LS174T 肿瘤的小鼠接受 micro-SPECT/CT 成像和荧光图像引导切除。在最后一个转化实验中,我们将新鲜切除的人肿瘤标本与示踪剂孵育,并评估两种信号的肿瘤与邻近组织的比值。
[In]In-DTPA-SGM-101 的最佳蛋白剂量为 30μg(肿瘤与血液的比值为 5.8±1.1),最佳成像时间点为注射后 72 小时(肿瘤与血液的比值为 5.1±1.0)。在患有腹腔内肿瘤的小鼠中,[In]In-DTPA-SGM-101 可进行术前 SPECT/CT 成像和荧光图像引导切除。孵育人肿瘤样本后,与相邻非肿瘤组织相比,肿瘤区域的总荧光和放射性信号强度更高(<0.001)。
[In]In-DTPA-SGM-101 在结直肠肿瘤中表现出特异性积聚,并可进行 micro-SPECT/CT 成像和荧光图像引导肿瘤切除。因此,[In]In-DTPA-SGM-101 可能是术前 SPECT/CT 成像以及术中放射性引导定位和荧光图像引导结直肠癌切除的有价值工具。